Physician profile
Jon A Raso
NPI 1609080175
$20,745.09
in general payments reported to CMS, 2019-2025
62 companies · $47.17 in 2025
The $47.17 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,561 · 2020: $3,066 · 2021: $3,917 · 2022: $4,116 · 2023: $4,352 · 2024: $1,687 · 2025: $47.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,078 · Education: $7.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,078.44 |
| Education | $7.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,085.71 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $1,500.22 | 2019-2024 | Repatha, Otezla |
| Abbvie INC. | $1,451.78 | 2020-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,266.36 | 2019-2023 | Xifaxan |
| Glaxosmithkline, LLC. | $1,120.44 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $1,116.25 | 2019-2024 | |
| Lilly USA, LLC | $1,113.78 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $1,088.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $959.28 | 2019-2024 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $799.93 | 2019-2024 | Jardiance, Tradjenta, Synjardy |
| Merck Sharp & Dohme LLC | $709.72 | 2019-2023 | Verquvo |
| Takeda Pharmaceuticals U.S.A., INC. | $685.03 | 2019-2024 | Trintellix, Takhzyro, Gattex |
| Janssen Pharmaceuticals, INC | $655.79 | 2019-2024 | Xarelto, Spravato |
| Bausch Health US, LLC | $636.23 | 2019-2024 | Aplenzin, Wellbutrin |
| Amarin Pharma, INC. | $600.86 | 2019-2021 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Raso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.